- Home
- TAC vs BLTE Comparison
TAC vs BLTE Comparison
Compare TAC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TAC | BLTE |
|---|---|---|
| Founded | 1909 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.1B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | TAC | BLTE |
|---|---|---|
| Price | $12.71 | $156.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $21.63 | ★ $149.00 |
| AVG Volume (30 Days) | ★ 1.3M | 296.8K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,783,342,546.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.82 | $49.00 |
| 52 Week High | $17.88 | $162.00 |
Technical Indicators
Market Signals| Indicator | TAC | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 30.22 | 65.90 |
| Support Level | $12.34 | $153.00 |
| Resistance Level | $15.24 | $158.50 |
| Average True Range (ATR) | 0.52 | 7.12 |
| MACD | -0.11 | -0.97 |
| Stochastic Oscillator | 1.73 | 68.08 |
Price Performance
Historical ComparisonAbout TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, Hydro, Wind & Solar, Energy Marketing, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.